Implication of FDG-PET/CT in patients with potentially operable colorectal lung metastases

Anton Uporov; Samantha Taber; Lope Estèvez Schwarz; Joern Groene; Lothar R Pilz; Gregor Foerster; Roland Bittner; Joachim Pfannschmidt

doi:10.1515/iss-2021-0029

Implication of FDG-PET/CT in patients with potentially operable colorectal lung metastases

Innov Surg Sci. 2021 Dec 24;6(3):89-95. doi: 10.1515/iss-2021-0029. eCollection 2022 Jan 17.

Authors

Anton Uporov¹, Samantha Taber¹, Lope Estèvez Schwarz², Joern Groene², Lothar R Pilz³, Gregor Foerster⁴, Roland Bittner⁴, Joachim Pfannschmidt¹

Affiliations

¹ Department of Thoracic Surgery, Heckeshorn Lung Clinic - HELIOS Klinikum Emil von Behring, Berlin, Germany.
² Department of Surgery, St. Joseph-Hospital, Berlin, Germany.
³ Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
⁴ Department of Radiology and Nuclear Medicine, HELIOS Klinikum Emil von Behring, Berlin, Germany.

Abstract

Objectives: This prospective study assessed the role of F-18-FDG-PET/CT in clinical staging for patients with colorectal cancer planned for pulmonary metastasectomy by thoracotomy or video-assisted surgery.

Patients and methods: In addition to conventional imaging, we performed 86 F-18-FDG-PET/CT studies in 76 patients with potentially resectable metastatic colorectal lung metastases. We then investigated the effect that PET/CT had on further clinical management. Based on the results from the 47 thoracotomies performed, we compared the number of pulmonary metastases discovered after histologic examination with the number predicted by the conventional computed tomography (CT) as an independent part of the F-18-FDG-PET/CT examination and by the F-18-FDG-PET component.

Results: F-18-FDG-PET/CT led to changes in treatment regime and diagnostic planning in many patients. In five patients PET/CT revealed previously undetected local recurrence of the primary colorectal cancer, in four patients hepatic metastases, in three patients bone metastases, in two patients soft-tissue metastases, and in three patients histologically preoperatively proven N2 or N3 station lymph node involvement. These all constituted exclusion criteria, and consequently the previously planned pulmonary metastasectomy was not performed. The sensitivity and positive predictive value (PPV) for detection of pulmonary metastases were 84.2% and 36.4% for CT and 75.0% and 61.6% for F-18-FDG-PET study. The calculated sensitivity, specificity, PPV, and NPV of F-18-FDG-PET/CT for detecting thoracic lymph node involvement were 85.7%, 93.0%, 66.7%, and 97.5%, respectively. Furthermore, we found that F-18-FDG-PET/CT may predict thoracic lymph node involvement based on the SUV of pulmonary nodules.

Conclusions: F-18-FDG-PET/CT has a clear role in the diagnostic workup for pulmonary metastatic colorectal cancer and may save patients from futile surgery. It cannot, however, be relied on to detect all possible pulmonary and nodal metastases, which surgeons must always consider when making treatment decisions.

Keywords: PET/CT; colorectal cancer; lung metastasis; staging; thoracic surgery.